首页> Clinical infectious diseases : an official publication of the Infectious Diseases Society of America> Safety and Immunogenicity of a Fourth Dose of Omicron BA.1-Adapted BNT162b2 COVID-19 Vaccines in Adults 18-55 Years Old.

Safety and Immunogenicity of a Fourth Dose of Omicron BA.1-Adapted BNT162b2 COVID-19 Vaccines in Adults 18-55 Years Old.

导出 OA

翻译打印收藏纠错

第一作者： Patricia,Winokur

第一单位： Division of Infectious Diseases, Carver College of Medicine, University of Iowa, Iowa City, Iowa, USA.

作者： Patricia,Winokur ^[1] ; Oyeniyi,Diya ^[2] ; David,Fitz-Patrick ^[3] ; Michael,Dever ^[4] ; Juleen,Gayed ^[2] ; Stephen,Lockhart ^[2] ; Xia,Xu ^[5] ; Ying,Zhang ^[6] ; Vishva,Bangad ^[5] ; L Tyler,Wadsworth ^[7] ; Kevin,Cannon ^[8] ; Jose F,Cardona ^[9] ; Lisa,Usdan ^[10] ; John,Ginis ^[5] ; Federico J,Mensa ^[11] ; Jing,Zou ^[12] ; Xuping,Xie ^[12] ; Claire,Lu ^[6] ; Sandra,Buitrago ^[6] ; Ingrid L,Scully ^[6] ; David,Cooper ^[6] ; Kenneth,Koury ^[6] ; Kathrin U,Jansen ^[6] ; Özlem,Türeci ^[11] ; Uğur,Şahin ^[11] ; Kena A,Swanson ^[6] ; William C,Gruber ^[6] ; Nicholas,Kitchin ^[2]

作者单位： Division of Infectious Diseases, Carver College of Medicine, University of Iowa, Iowa City, Iowa, USA. ^[1] Vaccine Research and Development, Pfizer Ltd, Hurley, United Kingdom. ^[2] East-West Medical Research Institute, Honolulu, Hawaii, USA. ^[3] Clinical Neuroscience Solutions, Orlando, Florida, USA. ^[4] Vaccine Research and Development, Pfizer Inc, Collegeville, Pennsylvania, USA. ^[5] Vaccine Research and Development, Pfizer Inc, Pearl River, NewYork, USA. ^[6] Sundance Clinical Research, St Louis, Missouri, USA. ^[7] PMG Research of Wilmington, Wilmington, North Carolina, USA. ^[8] Indago Research & Health Center, Inc, Hialeah, Florida, USA. ^[9] CNS Healthcare, Memphis, Tennessee, USA. ^[10] BioNTech, Mainz, Germany. ^[11] Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, Texas, USA. ^[12]

关键词 BA.1 BNT162b2 COVID-19 Omicron SARS-CoV-2